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of SSRI therapy in PCP settings. Eligible depressed
patients were randomized to treatment (N = 601) and 
naturalistically followed for 9 months. Medication use
was determined by self-report questionnaire. Adequate
treatment was deﬁned as six months continuous medica-
tion. Clinical response was determined by use of the 
SCL-20. Patients were classiﬁed as achieving remission
(score £6), partial response (50% decrease in symptoms),
or non-response. Baseline and end-of-study depression
severity and functioning were compared between groups
deﬁned by response and treatment classiﬁcations. 
RESULTS: Clinical response in this setting was less than
optimal with 45% of adequately treated patients classi-
ﬁed as non-responders. For remitters and partial respon-
ders, the greatest decreases in depression severity were by
the third month. Partial responders had greater depres-
sion severity and lower functioning at baseline and more
severe depression and lower level of functioning than
remitters at the 9-month evaluation. 
CONCLUSIONS: A substantial number of patients were
classiﬁed as non-responders despite adequate treatment
for six months. These patients may be considered under-
treated according to treatment guidelines recommending
dose increases or medication switches for non-responders.
Partial responders are often considered clinically im-
proved in studies, however they were signiﬁcantly more
ill than remitters following treatment.
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OBJECTIVE: To assess the development of costs for
dementia in Germany until the year 2050 under different
demographic scenarios and the possible impact of treat-
ment interventions with AChE inhibitors from various
perspectives. 
METHODS: A model to estimate cost differences in
dementia treatment with AChE inhibitors compared to 
a placebo scenario was developed. The model projects 
the number of dementia patients in Germany until 2050
under the assumption of extended life expectancy and
immigration. Markov modeling allows to document the
progression of dementia patients into more severe stages.
Data of the population development were supplied by the
Federal Bureau of Statistics and the German Institute for
Economic Research. Number of patients were calculated
from demographic prognoses considering prevalence of
disease data from a published meta-analyses of the epi-
demiology of dementia. Data about transition probabili-
ties between different disease stages were derived from a
randomized clinical trial of an AChE inhibitor. Disease
stage speciﬁc costs were taken from a cost of illness study
previously published. 
RESULTS: The number of dementia patients will increase
from 1 million to 2.5 million over the next 50 years in
Germany. With treatment there will be 30% less patients
in the most severe, and hence most costly disease stage.
Costs for treatment are offset by cost savings through a
shift of patients to less severe disease stages, if indirect
family and caring costs are included. Reduction of direct
costs due to treatment increase from 0.5 to 1.5 billion
Euro per year and indirect cost reductions are 4-fold these
ﬁgures. For 2000 net savings of 1.4 billion Euro are
demonstrated for the societal perspective. Results are
stable for extensive sensitivity analysis. 
CONCLUSION: Results document that the dimension 
of cost for care should make dementia a health policy 
priority. In an ageing society dementia treatment is also
economically highly attractive.
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OBJECTIVE: To examine the extent to which length 
of observation affects appropriate identiﬁcation of 
concomitant diagnoses. 
METHODS: Study was conducted using IMS HEALTH’s
LifeLinkTM database, a U.S. employer claims database
consisting of more than 1.8 million covered lives, with
linked medical and pharmacy claims for employees,
dependents, and retirees from 1991 forward. All patients
who had at least one claim for Type II diabetes between
April 1, 2000 and September 30, 2000 were selected.
Additionally, patients were required to be continuously
eligible for the entire 36 months preceding their diagno-
sis to ensure complete data. All diagnoses recorded on
medical claims in 6, 12, 24, and 36-month periods pre-
ceding the diabetes diagnosis were summarized at the 3-
digit ICD-9-CM level. Each time period was cumulative,
such that, patients in the 6-month period also were
observed in the 12-, 24- and 36-month periods, and the
number of patients identiﬁed with a comorbid condition
accumulated across the periods. 
RESULTS: 43,640 patients met the inclusion criteria. 
In comparing the percent of patients with comorbid 
conditions in a six-month observation period versus a 36-
month observation period, the percent of patients with
comorbid conditions increased dramatically. Large 
percentage increases between the 6-month to 36-month
observation periods were found for numerous chronic
comorbidities. For example, the percentage of type II 
diabetics with transient cerebral ischemia increased from
1.9% to 6.5% (243% increase). Other increases included:
depressive disorder (228%), angina (227%), hypertensive
